Private company

EQRx, Inc.

Pharmaceutical preparations company¹

In its 2023 annual report the company says: “We are a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions. It is now possible to engineer novel molecules around well-known targets, as evidenced by the increase in innovative but overlapping drug candidates with their own intellectual property.”⁵² It is headquartered in Cambridge, Massachusetts.¹

Last updated Oct 20, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersCambridge, Massachusetts¹
Business address50 Hampshire Street, Cambridge, Ma 02139²
Filer categoryLarge accelerated filer²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴-$355.9M in 2022+42% since 2020

Net income³⁴-$169.1M in 2022−32% since 2020

Fiscal year	2020	2021	2022
Research and development	$224.4M³	$118.1M⁴	$228.5M⁴
Operating expenses		$196.4M⁴	$355.9M⁴
Operating income	-$250.1M³	-$196.4M⁴	-$355.9M⁴
Income before tax		-$100.0M⁴	-$169.1M⁴
Income tax	$0³	$0⁴	$0⁴
Net income	-$250.0M³	-$100.0M⁴	-$169.1M⁴
Earnings per share	-$1.81³	-$0.31⁴	-$0.36⁴
Earnings per share (diluted)	-$1.81³	-$0.31⁴	-$0.36⁴
Shares (weighted, basic)		324.0M shares⁴	474.3M shares⁴
Shares (weighted, diluted)		324.0M shares⁴	474.3M shares⁴

Total assets³⁴$1.5B in 2022+191% since 2020

Total liabilities³⁴$66.2M in 2022+259% since 2020

Shareholders’ equity³⁴$1.4B in 2022

Cash³⁴$494.1M in 2022+2457% since 2019

Fiscal year	2019	2020	2021	2022	2023
Cash	$19.3M³	$489.7M³	$1.7B⁴	$494.1M⁴
Current assets		$492.3M³	$1.7B⁴	$1.4B⁴
Property, plant and equipment			$2.0M⁴	$2.6M⁴
Total assets		$500.5M³	$1.7B⁴	$1.5B⁴
Accounts payable			$7.6M⁴	$19.9M⁴
Current liabilities		$14.2M³	$39.6M⁴	$51.9M⁴
Total liabilities		$18.4M³	$214.6M⁴	$66.2M⁴
Retained earnings			-$358.5M⁴	-$527.6M⁴
Shareholders’ equity	-$8.5M³	$482.1M³	$1.5B⁴	$1.4B⁴
Shares outstanding		298.3M shares³	469.4M shares⁴	478.7M shares⁴	488.6M shares⁴

Cash from operations³⁴-$287.3M in 2022+19% since 2020

Capital spending³⁴$1.1M in 2022−62% since 2020

Free cash flow³⁴-$288.4M in 2022+18% since 2020

Fiscal year	2020	2021	2022
Cash from operations	-$241.5M³	-$183.2M⁴	-$287.3M⁴
Depreciation and amortization		$1.2M⁴	$935.0K⁴
Stock-based compensation		$26.2M⁴	$41.6M⁴
Capital spending	$3.0M³	$448.0K⁴	$1.1M⁴
Free cash flow	-$244.5M	-$183.6M	-$288.4M
Cash from investing		-$4.4M⁴	-$897.3M⁴
Cash from financing		$1.4B⁴	$139.0K⁴

Compare EQRx, Inc. with another company

Corporate structure

EQRx, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of EQRx, Inc.

AH Bio Fund II, L.P. Filed SC 13D/A on EQRx, Inc., latest Nov 17, 2023 (2 filings since Dec 27, 2021)
ARCH Venture Fund X, L.P. Filed SC 13G/A on EQRx, Inc., latest Nov 17, 2023 (2 filings since Feb 11, 2022)
Andreessen Horowitz Fund I, L.P. Filed SC 13D/A on EQRx, Inc., latest Nov 15, 2023
Casdin Capital, LLC Filed SC 13D/A on EQRx, Inc., latest Nov 15, 2023 (2 filings since Nov 29, 2022)
VANGUARD GROUP INC Filed SC 13G on EQRx, Inc., latest Feb 9, 2023
SOFTBANK GROUP CORP. Filed SC 13D/A on EQRx, Inc., latest Jan 18, 2023
CITADEL ADVISORS LLC Filed SC 13G/A on EQRx, Inc., latest Feb 14, 2022 (2 filings since Dec 10, 2021)
GV 2019, L.P. Filed SC 13G on EQRx, Inc., latest Feb 14, 2022
Eli Casdin Filed SC 13D on EQRx, Inc., latest Dec 30, 2021
SB Management Ltd Filed SC 13D on EQRx, Inc., latest Dec 27, 2021

EQRx, Inc. Cambridge, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What EQRx, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, before depreciation	$3.5M³ Dec 31, 2021	$3.1M³ Dec 31, 2020	+14.7%
Accumulated depreciation	$1.5M³ Dec 31, 2021	$338.0K³ Dec 31, 2020	+350.0%
Property and equipment, net	$2.6M⁴ Dec 31, 2022	$2.0M⁴ Dec 31, 2021	+32.3%
Operating-lease assets (leased space)	$3.8M⁴ Dec 31, 2022	$2.7M⁴ Dec 31, 2021	+42.4%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$494.1M⁴ Dec 31, 2022	$1.7B⁴ Dec 31, 2021	−70.6%
Marketable securities, current	$905.1M⁴ Dec 31, 2022
Debt securities available for sale	$905.1M⁴ Dec 31, 2022

Leadership

Who has led EQRx, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Eli Casdin2021

Chair

Alexis Borisy2023

Chief financial officer

2025

Chief executive officerEli Casdin Apr 6, 2021 to Aug 3, 2021⁷
ChairAlexis Borisy Jan 4, 2023 to Nov 9, 2023⁸
Chief financial officerBrian Emes Apr 6, 2021 to Apr 6, 2021⁹
Chief financial officerJami Rubin Dec 20, 2021 to Jan 4, 2023¹⁰

Board members and other officers (17)

Chief Strategy OfficerShaun Rodriguez Apr 6, 2021 to Apr 6, 2021¹¹
Chief Physician ExecutiveEric Hedrick Dec 20, 2021 to Jan 4, 2023¹²
Board memberChad M. Robins Apr 6, 2021 to Apr 6, 2021¹³
Board memberChristian O. Henry Apr 6, 2021 to Apr 6, 2021¹⁴
Board memberEli Casdin Apr 6, 2021 to Oct 4, 2022⁷
Board memberHarlan S. Robins Apr 6, 2021 to Apr 6, 2021¹⁵
Board memberKwame Owusu-Kesse Apr 6, 2021 to Apr 6, 2021¹⁶
Board memberAmy Abernethy Aug 3, 2021 to Nov 9, 2023¹⁷
Board memberAlexis Borisy Dec 20, 2021 to Dec 21, 2021¹⁸
Board memberClive Meanwell Dec 20, 2021 to Nov 9, 2023¹⁹
Board memberKathryn E. Giusti Dec 20, 2021 to Nov 9, 2023²⁰
Board memberKrishna Yeshwant Dec 20, 2021 to Nov 9, 2023²¹
Board memberPaul L. Berns Dec 20, 2021 to Nov 9, 2023²²
Board memberSamuel J. Merksamer Dec 20, 2021 to Nov 9, 2023²³
Board memberSandra Horning Dec 20, 2021 to Nov 9, 2023²⁴
Board memberJorge Conde Dec 21, 2021 to Nov 9, 2023²⁵
General counselDina Ciarimboli Mar 1, 2022 to Nov 9, 2023²⁶

Former names

CM Life Sciences III Inc.Feb 25, 2021 to Dec 17, 2021²

Timeline

Nov 9, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights²⁷
Nov 1, 20238-K Other events²⁸
Aug 3, 20238-K Ended a material agreement; Exit or restructuring costs²⁹
Aug 1, 20238-K Entered a material agreement; Regulation FD disclosure; Other events³⁰
May 8, 20238-K Ended a material agreement; Results of operations; Exit or restructuring costs³¹
Mar 13, 20238-K Executive or director change³²
Feb 23, 20238-K Results of operations; Exit or restructuring costs³³
Jan 11, 20238-K Results of operations; Regulation FD disclosure³⁴
Nov 25, 20228-K Executive or director change³⁵
Nov 10, 20228-K Results of operations³⁶
Oct 3, 20228-K Shareholder vote³⁷
Aug 11, 20228-K Results of operations³⁸
Apr 6, 2021New chief executive Eli Casdin becomes CEO⁷

Calendar

When it reported results

May 8, 2023Reported quarterly or annual results³¹
Feb 23, 2023Reported quarterly or annual results³³
Jan 11, 2023Reported quarterly or annual results³⁴
Nov 10, 2022Reported quarterly or annual results³⁶
Aug 11, 2022Reported quarterly or annual results³⁸
May 13, 2022Reported quarterly or annual results³⁹
Mar 23, 2022Reported quarterly or annual results⁴⁰
Jan 10, 2022Reported quarterly or annual results⁴¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

184 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 20 major events, 69 insider forms, 14 large holders, 71 other. The latest 20:

Nov 20, 202315-12G EDGAR
Nov 17, 2023EFFECT EDGAR
Nov 17, 2023EFFECT EDGAR
Nov 17, 2023EFFECT EDGAR
Nov 17, 2023SC 13D/A EDGAR
Nov 17, 2023SC 13G/A ARCH VENTURE FUND X, L.P. - EQRX, INC. -- SCH 13G/A(#1E) EDGAR
Nov 15, 2023SC 13D/A EDGAR
Nov 15, 2023SC 13D/A EDGAR
Nov 14, 20234 EDGAR
Nov 9, 2023POS AM EDGAR
Nov 9, 2023POS AM EDGAR
Nov 9, 2023S-8 POS EDGAR
Nov 9, 2023S-8 POS EDGAR
Nov 9, 2023POS AM EDGAR
Nov 9, 20238-K EDGAR
Nov 9, 20234 FORM 4 SUBMISSION EDGAR
Nov 9, 20234 FORM 4 SUBMISSION EDGAR
Nov 9, 20234 FORM 4 SUBMISSION EDGAR
Nov 9, 20234 FORM 4 SUBMISSION EDGAR
Nov 9, 20234 FORM 4 SUBMISSION EDGAR

The 184 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

AH Bio Fund II, L.P.SC 13D/A, 2 filings Dec 27, 2021 to Nov 17, 2023⁴²
ARCH Venture Fund X, L.P.SC 13G/A, 2 filings Feb 11, 2022 to Nov 17, 2023⁴³
Andreessen Horowitz Fund I, L.P.SC 13D/A, 1 filing Nov 15, 2023⁴⁴
Casdin Capital, LLCSC 13D/A, 2 filings Nov 29, 2022 to Nov 15, 2023⁴⁵
VANGUARD GROUP INCSC 13G, 1 filing Feb 9, 2023⁴⁶
SOFTBANK GROUP CORP.SC 13D/A, 1 filing Jan 18, 2023⁴⁷
CITADEL ADVISORS LLCSC 13G/A, 2 filings Dec 10, 2021 to Feb 14, 2022⁴⁸
GV 2019, L.P.SC 13G, 1 filing Feb 14, 2022⁴⁹
Eli CasdinSC 13D, 1 filing Dec 30, 2021⁵⁰
SB Management LtdSC 13D, 1 filing Dec 27, 2021⁵¹

SEC filer profile

How EQRx, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGAREQRx, Inc.¹
CIK0001843762
Employer ID (EIN)86-1691173¹
Filer statusLarge accelerated filer¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
Business address50 Hampshire Street, Cambridge, MA 02139¹
Phone(617) 315-2255¹
Shares outstanding487,696,181 as of Oct 27, 2023⁶
Public float$1.6B as of Jun 30, 2022⁴
On EDGAR sinceFeb 25, 2021¹
Filings233 in all: 4 (53), 425 (38), 8-K (25), 3 (22), CORRESP (11), 10-Q (9), EFFECT (9), UPLOAD (8)¹
All 35 form types
424B3 (7), SC 13D/A (5), POS AM (4), S-4/A (4), SC 13G (4), 4/A (3), SC 13D (3), 10-K (2), DEFA14A (2), S-1 (2), S-3 (2), S-8 (2), S-8 POS (2), SC 13G/A (2), SEC STAFF LETTER (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DEF 14A (1), DEFM14A (1), NT 10-Q (1), S-1/A (1), S-1MEF (1), S-4 (1)
Latest filingsAnnual report (10-K) Feb 23, 2023
Quarterly report (10-Q) Nov 6, 2023
Proxy statement (DEF 14A) Aug 12, 2022
Latest 8-K (8-K) Nov 9, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAREQRx, Inc. filings on SEC EDGAR
2
SEC EDGAREQRx, Inc. filings on SEC EDGAR
3
SEC EDGAREQRx, Inc. 10-K for fiscal 2020
4
SEC EDGAREQRx, Inc. 10-K for fiscal 2021
5
SEC EDGAREQRx, Inc. 10-Q for fiscal 2023
6
SEC EDGAREQRx, Inc. 10-Q for fiscal 2023
7
SEC EDGAREli Casdin, Chief executive officer
8
SEC EDGARAlexis Borisy, Chair
9
SEC EDGARBrian Emes, Chief financial officer
10
SEC EDGARJami Rubin, Chief financial officer
11
SEC EDGARShaun Rodriguez, Chief Strategy Officer
12
SEC EDGAREric Hedrick, Chief Physician Executive
13
SEC EDGARChad M. Robins, Board member
14
SEC EDGARChristian O. Henry, Board member
15
SEC EDGARHarlan S. Robins, Board member
16
SEC EDGARKwame Owusu-Kesse, Board member
17
SEC EDGARAmy Abernethy, Board member
18
SEC EDGARAlexis Borisy, Board member
19
SEC EDGARClive Meanwell, Board member
20
SEC EDGARKathryn E. Giusti, Board member
21
SEC EDGARKrishna Yeshwant, Board member
22
SEC EDGARPaul L. Berns, Board member
23
SEC EDGARSamuel J. Merksamer, Board member
24
SEC EDGARSandra Horning, Board member
25
SEC EDGARJorge Conde, Board member
26
SEC EDGARDina Ciarimboli, General counsel
27
SEC EDGARCompleted an acquisition or sale; Listing notice or transfer; Change to shareholders' rights
28
SEC EDGAROther events
29
SEC EDGAREnded a material agreement; Exit or restructuring costs
30
SEC EDGAREntered a material agreement; Regulation FD disclosure; Other events
31
SEC EDGAREnded a material agreement; Results of operations; Exit or restructuring costs
32
SEC EDGARExecutive or director change
33
SEC EDGARResults of operations; Exit or restructuring costs
34
SEC EDGARResults of operations; Regulation FD disclosure
35
SEC EDGARExecutive or director change
36
SEC EDGARResults of operations
37
SEC EDGARShareholder vote
38
SEC EDGARResults of operations
39
SEC EDGAREQRx, Inc. 8-K, Item 2.02 (results of operations)
40
SEC EDGAREQRx, Inc. 8-K, Item 2.02 (results of operations)
41
SEC EDGAREQRx, Inc. 8-K, Item 2.02 (results of operations)
42
SEC EDGARAH Bio Fund II, L.P. SC 13D/A on EQRx, Inc.
43
SEC EDGARARCH Venture Fund X, L.P. SC 13G/A on EQRx, Inc.
44
SEC EDGARAndreessen Horowitz Fund I, L.P. SC 13D/A on EQRx, Inc.
45
SEC EDGARCasdin Capital, LLC SC 13D/A on EQRx, Inc.
46
SEC EDGARVANGUARD GROUP INC SC 13G on EQRx, Inc.
47
SEC EDGARSOFTBANK GROUP CORP. SC 13D/A on EQRx, Inc.
48
SEC EDGARCITADEL ADVISORS LLC SC 13G/A on EQRx, Inc.
49
SEC EDGARGV 2019, L.P. SC 13G on EQRx, Inc.
50
SEC EDGAREli Casdin SC 13D on EQRx, Inc.
51
SEC EDGARSB Management Ltd SC 13D on EQRx, Inc.
52
SEC EDGAREQRx, Inc. filing with the SEC